Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanbeizhuhan Capsule is a traditional Chinese medicine (TCM) developed by Dongyang Baorentang Pharmaceutical for the treatment of obstructive sleep apnea hypopnea syndrome (OSAHS). The formulation is specifically designed for patients presenting with the phlegm-blood stasis TCM pattern, aiming to resolve phlegm and remove blood stasis to alleviate airway obstruction. It has been evaluated in Phase 2 clinical trials in China (e.g., CTR20131826) to assess its efficacy and safety in adults with mild to moderate OSAHS. The drug represents a botanical approach to managing sleep-disordered breathing by addressing underlying pathological factors defined within the TCM framework.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanbeizhuhan Capsule.